Alpine Clinical Research Center

Main menu

Skip to content
  • Home
  • Current Research Studies
  • For Participants
  • For Sponsors
  • Contact

Trial Archives: Completed

Post navigation

← Older trials
Newer trials →

New Study Medication for Patients with Secondary Progressive Multiple Sclerosis

- December 5, 2013

Newly Approved Medication for Multiple Sclerosis

- December 5, 2013

New Investigational Medication for patients with moderate to severe COPD (chronic obstructive pulmonary disease)

- September 17, 2012

New Investigational Medication for Postherpetic Neuralgia (PHN/Shingles)

- September 17, 2012

Newly approved medication for Multiple Sclerosis

- June 29, 2012

Investigational medication for pediatric patients with Autism, Asperger’s disorder, or Pervasive developmental disorder.

- May 8, 2012

Newly approved medication for subjects in early stages of treatment for Relapsing Remitting Multiple Sclerosis

- May 8, 2012

Protocol: F-AV-45-A17 PET scan using an investigational radioactive drug to help determine the likely cause of cognitive decline.

- May 8, 2012

Protocol: DS5565-A-U201 New Investigational Medication for Diabetic Peripheral Neuropathy

- May 8, 2012

Protocol: ROF-MD-07 New Investigational Medication for Severe Chronic Obstructive Pulmonary Disease (COPD)

- May 8, 2012

Protocol: P07037 New Investigational Medication for Moderate to Severe Parkinson’s Disease

- August 23, 2011

Medication for Painful Diabetic Peripheral Neuropathy

- April 22, 2011

Protocol 109MS302, Biogen, Multiple Sclerosis

- March 31, 2011

Protocol F1J-US-HMFR, Eli-Lilly, Neuropathic Pain in Multiple Sclerosis

- March 31, 2011

Protocol F1J-US-HMGL, Eli Lilly, Osteoarthritis of the Knee

- March 24, 2011

Post navigation

← Older trials
Newer trials →

Our CenterWatch Profile

Alpine Clinical Research Center on CenterWatch

Alpine Clinical Research Center - 3434 47th Street, Suite 201 - Boulder, CO 80301
phone: 303.443.7229 | fax: 303.443.7748 | email: info@alpineresearch.com
site by: Lenfert Design